Merck Announces First Presentation of Early Data on the Investigational Use of KEYTRUDA® (pembrolizumab) in Patients with Advanced Bladder Cancer at ESMO 2014
Dateline City:
WHITEHOUSE STATION, N.J.
KEYTRUDA® monotherapy achieved 24 percent overall response rate in patients with PD-L1 positive, advanced bladder (urothelial) cancer
Planned Phase 3 study in advanced bladder cancer to be initiated by the end of 2014
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the first presentation of data on the investigational
use of KEYTRUDA® (pembrolizumab) – the company’s anti-PD-1
therapy – in PD-L1 positive, advanced urothelial cancer (also known as
bladder cancer).
Language:
English
Contact:
MerckMedia:Ian McConnell, 973-901-5722Claire Mulhearn, 908-423-7425orInvestor:Joseph Romanelli, 908-423-5185Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News Source Type: news